Compare LSBK & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | INO |
|---|---|---|
| Founded | 1891 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 100.4M |
| IPO Year | 2025 | 1999 |
| Metric | LSBK | INO |
|---|---|---|
| Price | $16.99 | $1.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 8.5K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | 49.23 | ★ 54.18 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | $65.38 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $11.50 | $1.03 |
| 52 Week High | $17.96 | $2.86 |
| Indicator | LSBK | INO |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 51.80 |
| Support Level | $16.64 | $1.03 |
| Resistance Level | $17.76 | $1.24 |
| Average True Range (ATR) | 0.45 | 0.06 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 29.17 | 53.85 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.